peptides for FAQ

Thymalin addresses the immune-HPA axis dysfunction that conventional anxiolytics ignore entirely. Chronic cortisol elevation suppresses thymic function, reducing regulatory T-cell production and elevating IL-6 and TNF-alpha. Cytokines that directly stimulate hypothalamic CRH secretion. This creates a self-perpetuating stress-inflammation cycle. Thymalin 5–10mg subcutaneous every third day for 30 days restores T-cell maturation and cytokine balance. Monitor using inflammatory markers (hsCRP, IL-6) if accessible. The 2022 Peptides study showed 38% IL-6 reduction within 21 days. Combine with Thymosin Alpha 1 if immune compromise is severe; the compounds demonstrate synergistic immune restoration effects.

Start with Thymosin Alpha-1 Peptide at 1.6 mg subcutaneous twice weekly for 8–12 weeks. Autoimmune inflammation results from dysregulated T-cell activity and impaired regulatory T-cell (Treg) function. Thymosin Alpha-1 restores this balance by enhancing TLR signaling and promoting Treg differentiation, which suppresses autoreactive immune responses without causing broad immunosuppression. Clinical evidence in conditions like chronic hepatitis (which shares immune dysregulation features with autoimmune diseases) shows normalization of inflammatory markers and improved immune regulation. Add KPV 5MG at 500 mcg–1 mg daily if mucosal inflammation (gut, respiratory tract) is present—KPV's intracellular NF-κB inhibition complements Thymosin Alpha-1's immune modulation.

Combine BPC-157 Peptide at 250–400 mcg daily with TB-500 Thymosin Beta-4 at 2–5 mg twice weekly for 4–6 weeks. BPC-157's angiogenic effect delivers oxygen and immune cells to damaged tissue, accelerating the repair phase. TB-500 prevents the fibrotic remodeling that occurs when inflammation persists—scar tissue replaces functional tendon fibers, creating mechanical weakness and reinjury risk. This combination addresses both active inflammation and the structural consequences of chronic injury. Inject BPC-157 subcutaneously near the injury site (within 2–3 inches); administer TB-500 subcutaneously in abdominal or thigh tissue where absorption is consistent.

Combination protocols are common in research settings. Semax paired with SS-31 targets both neuroplasticity and mitochondrial function, while VIP combined with Selank addresses neuroinflammation and HPA axis dysregulation. Timing matters: administer mitochondrial peptides (SS-31) in the morning to align with circadian ATP demand peaks, and anxiolytic peptides (Selank) in late afternoon when cortisol should naturally decline. Stacking more than three peptides simultaneously introduces confounding variables that make outcome attribution difficult.

Transition to GHK-Cu during the remodeling phase. Weak scar tissue indicates insufficient collagen cross-linking or poor fibril alignment. Both correctable with copper-dependent enzymes. Apply GHK-Cu topically at 0.1% concentration twice daily for 8–12 weeks post-closure. A 2017 RCT in post-surgical scars found this regimen reduced hypertrophic scar formation by 53% and increased tensile strength (measured via durometry) by 34% compared to standard silicone therapy. Remodeling is the longest phase. Some wounds continue matrix reorganization for 12+ months.

Selank is the primary candidate due to its NF-kB inhibition and IL-10 upregulation. Patients with elevated CRP (C-reactive protein), IL-6, or TNF-alpha. Biomarkers increasingly measured in treatment-resistant depression. May have inflammation-driven MDD that SSRIs cannot address. Selank's anti-inflammatory mechanism directly targets microglial activation, the central nervous system's inflammatory response. A 2009 RCT found that Selank reduced anxiety and secondary depressive symptoms in GAD patients, with effects correlating to reduced peripheral cytokine levels. If baseline inflammatory markers are elevated, Selank's dual anxiolytic and anti-inflammatory profile makes it mechanistically aligned with the pathology.

Combine a GLP-1 agonist with an anti-inflammatory peptide like thymosin alpha-1 or KPV 5MG. Chronic low-grade inflammation is both a consequence and a cause of insulin resistance—visceral adipose tissue secretes TNF-alpha, IL-6, and resistin, which directly impair insulin receptor signaling and promote hepatic steatosis. Thymosin alpha-1 modulates T-regulatory cell function and reduces macrophage-derived inflammatory cytokines, while KPV (a tripeptide fragment of alpha-MSH) inhibits NF-kB activation and reduces inflammatory signaling in adipose tissue. This combination addresses both the metabolic dysfunction (via GLP-1 agonism) and the inflammatory milieu that perpetuates insulin resistance even after weight loss.

Consider switching from a single-mechanism peptide to a combination protocol. Stalled proliferation typically indicates either insufficient angiogenesis (hypoxic tissue can't support fibroblast activity) or impaired cell migration (extracellular matrix too dense or disorganized). Combine BPC-157 for angiogenesis with TB-500 for migration. Animal models suggest synergistic effects when both pathways are activated concurrently. A 2021 study in Tissue Engineering Part A showed combination BPC-157 + TB-500 reduced healing time by 52% compared to either peptide alone in full-thickness dermal wounds.

Oral bioavailability for KPV is severely limited by gastric peptidase degradation. Less than 5% reaches systemic circulation intact. Rectal or subcutaneous routes bypass first-pass metabolism and deliver higher concentrations to target tissues. If local colonic effect is the goal, rectal administration via enema provides direct mucosal contact at therapeutic concentrations without requiring systemic absorption.

Combine SS-31 or MOTS-C with an immune-modulating peptide such as thymosin alpha-1 or KPV. SS-31 addresses mitochondrial oxidative damage, while thymosin alpha-1 reduces inflammatory cytokine release that drives maladaptive remodeling. These mechanisms are complementary rather than redundant. Mitochondrial dysfunction and chronic inflammation represent two distinct but interconnected pathways driving heart failure progression. Preclinical models combining mitochondrial and immune-modulating peptides demonstrate additive protective effects that exceed either peptide administered alone.

Store unreconstituted lyophilised peptides at −20°C to maintain long-term stability. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days. Peptides reconstituted with standard saline degrade within 7 days even under refrigeration. If your protocol extends beyond 28 days, reconstitute smaller aliquots weekly rather than preparing the entire vial at once. Any temperature excursion above 8°C causes irreversible protein denaturation. A single overnight exposure to room temperature can eliminate therapeutic activity entirely, turning the preparation into inactive saline.

Use AMPK-activating peptides like MOTS-C or 5-Amino-1MQ rather than appetite-suppressing GLP-1 agonists. The metabolically obese normal weight (MONW) phenotype—normal BMI with elevated visceral fat and insulin resistance—responds poorly to caloric restriction because the problem isn't total energy intake but impaired mitochondrial glucose oxidation and ectopic fat deposition. MOTS-C enhances skeletal muscle glucose uptake by increasing GLUT4 translocation and mitochondrial respiratory capacity, which improves insulin sensitivity without requiring weight loss. Preclinical evidence shows MOTS-C reversed insulin resistance in lean animals fed high-fat diets, confirming the effect is metabolic rather than weight-dependent.

Cloudiness indicates aggregation or precipitation. Either from improper reconstitution technique, contaminated bacteriostatic water, or temperature fluctuations during storage. Do not use the solution. Protein aggregation alters pharmacokinetics and may trigger immune responses. Reconstitute a fresh vial using sterile bacteriostatic water at the specified concentration, and verify storage temperature remains between 2–8°C.

Administer TB-500 at 2.5mg twice weekly for 4–6 weeks to target the remodeling phase. By week three, the inflammatory phase has ended and proliferative activity (new muscle fiber formation) is tapering. TB-500's anti-fibrotic properties remain relevant because collagen remodeling continues through week 8. BPC-157's angiogenic effects are less critical after vascularization is established, so prioritize TB-500 and consider adding a GH secretagogue like CJC-1295/Ipamorelin to enhance collagen cross-linking during late-stage recovery.

TB-500 addresses the inflammatory component of trochanteric bursitis more directly than the other two. The peptide's actin-binding mechanism downregulates pro-inflammatory cytokines in the bursal sac while promoting tissue repair. Dosing protocols in pre-clinical studies used 2.5–5 mg twice weekly. BPC-157 could support adjacent tendon healing if gluteal tendinopathy is contributing, but TB-500's systemic anti-inflammatory effect makes it the primary choice for bursal inflammation.

Peptides accelerate repair, but they don't prevent new microtears if you continue high-impact training at the same volume. Reduce mileage by 40–50% and avoid hard surfaces (concrete, asphalt) during the peptide protocol. The goal is to create a net-positive repair environment where collagen synthesis outpaces tissue damage. Continuing full training load while using peptides wastes the compounds. You're repairing tissue as fast as you're tearing it.

Gradual load progression is safe and recommended. Peptides accelerate healing, but tissue strength lags behind pain reduction by 2–4 weeks. Feeling better doesn't mean the tissue is fully repaired. Start with pain-free range of motion exercises (passive leg swings, supine hip flexor stretches) at week 2–3. Progress to resistance training at 30–40% of pre-injury load by week 4, increasing 10% per week as long as pain remains absent. High-intensity plyometrics (sprinting, jumping) should wait until week 8–10 for Grade 2 strains, longer for Grade 3. Continuing peptides during the return-to-training phase supports the final remodeling stage and reduces re-injury risk.

Continue physical therapy while adding peptide support. BPC-157 and TB-500 modulate the inflammatory environment that prevents tissue remodelling, but they don't replace biomechanical correction. Research shows 85% of IT band syndrome cases involve hip abductor weakness or excessive hip adduction during gait, which foam rolling cannot address. Peptides accelerate tissue repair, but if the underlying movement pattern persists, re-injury is inevitable. Combine peptide protocols with targeted hip strengthening (glute medius activation, single-leg stability drills) for sustainable outcomes.

Reassess injury severity and peptide quality. If pain persists at the same level after three weeks, the strain may be more severe than initially assessed. Grade 2 or Grade 3 tears require imaging (MRI or ultrasound) to rule out complete rupture. Verify peptide source and storage: degraded BPC-157 loses activity but looks identical to fresh product. Switch to a verified supplier with third-party HPLC purity testing. Consider adding TB-500 to the protocol if you've been using BPC-157 alone. Some injuries respond better to combined angiogenesis and matrix remodeling than to angiogenesis alone.

Yes. Chronic cases respond to peptides, though the timeline extends. Start with TB-500 to restore blood flow to the periosteum first, then layer in BPC-157 after two weeks to initiate collagen repair once circulation improves. Chronic inflammation often creates a hypoxic tissue environment where fibroblasts can't function properly. TB-500's angiogenic effect reverses that before BPC-157 triggers collagen synthesis. Expect 4–6 weeks for noticeable improvement rather than the 3–4 weeks seen in acute cases.